NCT00240383
Who may be able to join
Who might be able to join this trial:
- You are between 18 and 70 years old (male or female)
- You have been diagnosed with Type 2 diabetes
- Your HbA1c blood sugar level (a measure of average blood sugar over time) was between 7.0% and 10.0% at your screening appointment
Who may not be able to join:
- You have severe diabetes symptoms, such as excessive thirst and frequent urination, along with losing more than 10% of your body weight in the last three months
- You have taken blood sugar-lowering medications (other than a specific type called thiazolidinediones) for more than three days in a row, or more than seven days total, in the four weeks before screening
- You have taken a type of diabetes medication called thiazolidinediones for more than three days in a row, or more than seven days total, in the six weeks before screening
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
To compare, after 24 weeks of oral administration of double-blind treatment, the change from baseline in hemoglobin A1c (HbA1c) achieved with the highest dose and subsequent doses of BMS-298585 versus the lowest dose of BMS-298585 in subjects with Type 2
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.